Samenvatting

The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.

Specificaties

ISBN13:9781009336130
Taal:Engels
Bindwijze:Paperback
Aantal pagina's:75

Lezersrecensies

Wees de eerste die een lezersrecensie schrijft!

Inhoudsopgave

1. Introduction; 2. ALK gene rearrangements; 3. ROSI gene rearrangements; 4. RET gene rearrangements; 5. MET alterations; 6. KRAS point mutations; 7. B-RAF point mutations; 8. NTRK1/2/3 gene fusions; 9. ERBB2 (HER2) mutations; 10. Diagnostic strategies; References.

Managementboek Top 100

€ 25,79
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Rubrieken

    Personen

      Trefwoorden

        Artikelen

          Targeting Oncogenic Driver Mutations in Lung Cancer